Spruce Street Capital LP — 13F Holdings & Portfolio
CIK 2050194 · latest 13F-HR filed 2026-05-14
Spruce Street Capital LP manages $415.9M in 13F-reported U.S. long-equity assets across 28 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are RLMD (10.34%), KNSA (8.81%), LBRX (8.09%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 7 new positions, exited 6, added to 17, and trimmed 3.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$415.9M
Long-equity book
28
Distinct positions
2026-03-31
Filed 2026-05-14
+7 / −6 / ↑17 / ↓3
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALTO NEUROSCIENCE INC$25.1M +634.0%
- RELMADA THERAPEUTICS INC$23.3M +117.9%
- DIANTHUS THERAPEUTICS IN$19.1M +155.6%
- KINIKSA PHARMACEUTICALS I$18.7M +104.2%
- CENTESSA PHARMACEUTICALS$17.5M +897.4%
Top Trims
- ERASCA INC-$7.6M -52.8%
- VAXCYTE INC-$4.2M -22.7%
- INHIBIKASE THERAPEUTI-$1.3M -18.0%
New Positions
- ALKERMES PLC$11.2M
- PERSPECTIVE THERAPEUTICS$11.0M
- ALUMIS INC$8.6M
- MAZE THERAPEUTICS INC$6.0M
- AN2 THERAPEUTICS INC$5.6M
Exited Positions
- CIDARA THERAPEUTICS INC$51.3M
- EYEPOINT INC$17.9M
- OCULAR THERAPEUTIX INC$9.5M
- ABIVAX SA$6.6M
- CYBIN INC$6.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $43.0M | 10.34% | 6,262,114 | SH |
| 2 | KINIKSA PHARMACEUTICALS I | KNSA | G52694109 | $36.6M | 8.81% | 761,063 | SH |
| 3 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $33.6M | 8.09% | 1,376,159 | SH |
| 4 | DIANTHUS THERAPEUTICS IN | DNTH | 252828108 | $31.3M | 7.53% | 373,274 | SH |
| 5 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $29.7M | 7.14% | 2,984,125 | SH |
| 6 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $29.1M | 7.00% | 1,325,210 | SH |
| 7 | CENTESSA PHARMACEUTICALS | CNTA | 152309100 | $19.5M | 4.68% | 489,849 | SH |
| 8 | SAVARA INC | SVRA | 805111101 | $18.5M | 4.44% | 3,383,175 | SH |
| 9 | KALVISTA PHARMACEUTICALS | KALV | 483497103 | $18.1M | 4.34% | 897,681 | SH |
| 10 | VAXCYTE INC | PCVX | 92243G108 | $14.3M | 3.43% | 245,709 | SH |
| 11 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $12.9M | 3.10% | 329,006 | SH |
| 12 | SURROZEN INC COM NEW | SRZN | 86889P208 | $12.6M | 3.03% | 432,040 | SH |
| 13 | ENANTA PHARMACEUTICALS I | ENTA | 29251M106 | $11.8M | 2.83% | 932,598 | SH |
| 14 | ALKERMES PLC | ALKS | G01767105 | $11.2M | 2.70% | 317,992 | SH |
| 15 | PERSPECTIVE THERAPEUTICS | CATX | 46489V302 | $11.0M | 2.63% | 2,627,107 | SH |
| 16 | MINERVA NEUROSCIENC | NERV | 603380205 | $10.0M | 2.40% | 1,655,500 | SH |
| 17 | CENTURY THERAPEUTICS | IPSC | 15673T100 | $9.2M | 2.21% | 4,059,054 | SH |
| 18 | ALUMIS INC | ALMS | 022307102 | $8.6M | 2.08% | 392,574 | SH |
| 19 | SAB BIOTHERAPEUTICS IN | SABS | 78397T202 | $8.4M | 2.02% | 2,198,502 | SH |
| 20 | ERASCA INC | ERAS | 29479A108 | $6.8M | 1.64% | 422,543 | SH |
| 21 | INHIBIKASE THERAPEUTI | IKT | 45719W205 | $6.0M | 1.45% | 3,581,603 | SH |
| 22 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $6.0M | 1.44% | 200,000 | SH |
| 23 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $5.6M | 1.34% | 1,661,073 | SH |
| 24 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $5.3M | 1.28% | 928,593 | SH |
| 25 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $5.1M | 1.22% | 500,000 | SH |
| 26 | ALECTOR INC | ALEC | 014442107 | $4.5M | 1.09% | 2,101,068 | SH |
| 27 | LEONABIO INC | LONA | 04746L203 | $3.8M | 0.92% | 393,701 | SH |
| 28 | CORVUS PHARMACEUTICALS I | CRVS | 221015100 | $3.4M | 0.81% | 231,585 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $415.9M | 28 | 0002050194-26-000004 |
| 2025-12-31 | 2026-02-13 | $302.7M | 27 | 0002050194-26-000001 |